Table 1.

Characteristics of the patients included in the clinical trials. (See Figures 2 and 3).

COHORT Treatment	Prospective cohort Sunitinib	Prospective cohort Bevacizumab	Prospective cohort of validation Sunitinib neoadjuvant
Trials (number of patients)	SUVEGIL (24) TORAVA (12)	TORAVA (34)	PREINSUT (13)
Number of patients	36	34	13
Gender
Female	6 (16.7%)	9 (26.5%)	3 (23.1%)
Male	30 (83.3%)	25 (73.5%)	10 (76.9%)
PRIMARY TUMOR
Fuhrman grade
1	1 (2.8%)	2 (5.9%)	0 (0%)
2	9 (25%)	8 (23.5%)	0 (0%)
3	17 (47.2%)	14 (41.2%)	6 (46.1%)
4	9 (25%)	10 (29.4%)	4 (30.8%)
X	0 (0%)	0 (0%)	3 (23.1%)
pT
1	8 (22.2%)	5 (14.7%)	1 (7.7%)
2	10 (27.8%)	5 (14.7%)	1 (7.7%)
3	16 (44.4%)	18 (52.9%)	8 (61.5%)
X	2 (5.6%)	6 (17.6%)	3 (23.1%)
pN
0	15 (41.7%)	0 (0%)	4 (30.8%)
1	5 (13.9%)	0 (0%)	2 (15.4%)
2	1 (2.7%)	0 (0%)	1 (7.7%)
X	15 (41.7%)	34 (100%)	6 (46.1%)
BEGINNING OF THE TREATMENT
Age at therapy initiation (yr)	60.4 (9.7)	58.7 (11.3)	63.5 (9.8)
Metastatic from the diagnosis	18 (50%)	14 (41.2%)	8 (61.5%)
Time from diagnosis to treatment
< 1 yr	23 (63.8%)	20 (58.8%)	9 (69.2%)
≥ 1 yr	13 (36.1%)	14 (41.2%)	4 (30.8%)
Number of metastatic sites
1	17 (47.2%)	17 (50%)	6 (46.1%)
2	13 (36.1%)	10 (29.4%)	6 (46.1%)
≥ 3	6 (16.7%)	7 (20.6%)	1 (7.7%)
Risk factor (MSKCC)
Good	10 (27.8%)	14 (41.2%)	0 (0%)
Intermediate	10 (27.8%)	18 (52.9%)	0 (0%)
Bad	8 (22.2%)	0 (0%)	0 (0%)
X	8 (22.2%)	2 (5.9%)	13 (100%)
Median followed (month)	34.5 (18.2-NR)	24 (23-NR)	NA